Download Free Medical Management and Therapies of Diabetes Mellitus PowerPoint Presentation

Management and Therapies of Diabetes Mellitus PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation is about comprehensive medical care in diabetes with individualized treatment, goals, plan, self-monitoring of blood glucose (SMBG), HbA1c testing and Lifestyle management.

Tags : Diabetes Mellitus, Management, Therapies, Detection, prevention, self-monitoring of blood glucose, SMBG, HbA1c testing, Blood pressure, Lipids, antiplatelet therapy, Influenza, pneumococcal, hepatitis B, immunizations

Published on : Apr 06, 2021 | Views : 3715 | Downloads : 17

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Diabetes Mellitus: Management and Therapies
Slide 2-

Comprehensive medical care in diabetes Individualized treatment goals and plan Self-monitoring of blood glucose (SMBG) HbA1c testing (2–4 times/year) Lifestyle management
Slide 3-

Detection, prevention, or management of diabetes-related complications, including: Diabetes-related eye examination Diabetes-related foot examination Diabetes-related neuropathy examination Diabetes-related kidney disease testing Manage or treat diabetes-relevant conditions, including: Blood pressure Lipids Consider antiplatelet therapy Influenza/pneumococcal/hepatitis B immunizations
Slide 4-

In short…
Slide 5-

Treatment goals for adults with diabetes Glycemic control HbA1c <7.0% Preprandial capillary plasma glucose 80–130 mg/dL (4.4–7.2 mmol/L) Postprandial capillary plasma glucosed <180 mg/dL ( <10.0 mmol/L) Blood pressure <140/90 mmHg
Slide 6-

Glucose lowering agents.. ORAL Biguanides Alpha glucosidase inhibitors DPP4 inhibitors Insulin secretagogues (sulphonylurea and nonsulphonylurea) SGLT2 inhibitors Thiazolidinediones
Slide 7-

PARENTRAL Amylin agoinst GLP1 agonist Insulin
Slide 8-

Insulin
Slide 9-

Regimen 1 One shot of long-acting insulin and three shots of short acting insulin to provide glycemic coverage for each meal.
Slide 10-

Regimen2 Injection of two shots of long-acting insulin (NPH) and short-acting insulin analogue (glulisine, lispro, insulin aspart [solid red line], or regular insulin [green dashed line]).
Slide 11-

Regimen 3 Insulin administration by insulin infusion device is shown with the basal insulin and a bolus injection at each meal.
Slide 12-

DIFFERNCES IN THE MANAGEMENT OF TYPE 1 AND TYPE 2 D.M…
Slide 13-

Type 2 D.M management algorithm
Slide 14-

Biguanides EXAMPLE- Metformin MOA- ↓ Hepatic glucose production ADVANTAGES- Weight neutral, do not cause hypoglycemia, inexpensive, extensive experience, ↓ CV events DISADVANTAGES-Diarrhea, nausea, lactic acidosis, vitamin B12 deficiency CONTRAINDICATIONS-Renal insufficiency (for GFR <45 mL/min), CHF, radiographic contrast studies, hospitalized patients, acidosis
Slide 15-

α-Glucosidase inhibitor EXAMPLE-Acarbose, miglitol, voglibose MOA- ↓ GI glucose absorption ADVANTAGES-Reduce postprandial glycemia DISADVANTAGES-GI flatulence, liver function tests CONTRAINDICATIONS-Renal/liver disease
Slide 16-

Dipeptidyl peptidase IV inhibitor EXAMPLE- Alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin MOA- Prolong endogenous GLP-1 action; ↑ Insulin, ↓ glucagon ADVANTAGES- Well tolerated, do not cause hypoglycemia DISADVANTAGES-Angioedema/ urticarial and immune-mediated dermatologic effects CONTRAINDICATIONS-Reduced dose with renal disease
Slide 17-

Insulin secretagogues: Sulfonylurea EXAMPLE- Glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glyburide, glyclopyramide MOA- ↑ Insulin secretion ADVANTAGES- Short onset of action, lower postprandial glucose, inexpensive DISADVANTAGES- Hypoglycemia, weight gain CONTRAINDICATIONS- Renal/liver disease
Slide 18-

Insulin secretagogues: Nonsulfonylureas EXAMPLE- Mitiglinide nateglinide, repaglinide MOA-↑ Insulin secretion ADVANTAGES-Short onset of action, lower postprandial glucose DISADVANTAGES- Hypoglycemia CONTRAINDICATIONS-Renal/liver disease
Slide 19-

Sodium-glucose cotransporter 2 inhibitors EXAMPLE-Canagliflozin, dapagliflozin, empagliflozin, ertugliflozin MOA-↑ renal glucose excretion ADVANTAGES-do not cause hypoglycemia, ↓ weight and BP DISADVANTAGES-Urinary and genital infections, polyuria, dehydration, exacerbate tendency to hyperkalemia and DKA CONTRAINDICATIONS-Moderate renal insufficiency, insulindeficient DM
Slide 20-

Thiazolidinedione EXAMPLE-Pioglitazone, rosiglitazone MOA- ↓ Insulin resistance, ↑ glucose utilization ADVANTAGES- Lower insulin requirements DISADVANTAGES-Peripheral edema, CHF, weight gain, fractures, macular edema CONTRAINDICATIONS-CHF, liver disease
Slide 21-

Amylin agonists EXAMPLE- Pramlintide MOA-Slow gastric emptying, ↓ glucagon ADVANTAGES- Reduce postprandial glycemia, weight loss DISADVANTAGES-Injection, nausea, ↑ risk of hypoglycemia with insulin CONTRAINDICATIONS-Agents that also slow GI motility
Slide 22-

GLP-1 receptor agonists EXAMPLE- Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide MOA-↑ Insulin, ↓ glucagon, slow gastric emptying, satiety ADVANTAGES-Weight loss, do not cause hypoglycemia DISADVANTAGES-Injection, nausea, ↑ risk of hypoglycemia with insulin secretagogues CONTRAINDICATIONS-Renal disease, agents that also slow GI motility; medullary carcinoma of thyroid, pancreatic disease
Slide 23-

BILE ACID BINDING RESINS BROMOCRIPTINE
Slide 24-

SURGICAL THERAPY… pancreas transplantation EMERGING THERAPIES
Slide 25-

Lifestyle management (1) diabetes self-management education (DSME) and diabetes self-management support (DSMS) (2) Nutrition therapy (3) Psychosocial care (4) Physical activity
Slide 26-

ACUTE DISORDERS RELATED TO SEVERE HYPERGLYCEMIA
Slide 27-

ppt slide no 27 content not found
Slide 28-

DKA Pathophysiology
Slide 29-

DKA management… 1. Confirm diagnosis 2. Admit to hospital 3. Assess: Serum electrolytes (K+, Na+, Mg2+, Cl–, bicarbonate, phosphate) Acid-base status—pH, HCO3–, Pco2 Renal function (creatinine, urine output)
Slide 30-

DKA management… 4. Replace fluids: 2–3 L of NS over first 1–3 h (10–20 mL/kg per hour) then half NS at 250–500 mL/h change to DNS at 150–250 mL/h when plasma glucose reaches 250 mg/dL (13.9 mmol/L).
Slide 31-

DKA management… 5. Administer short-acting regular insulin: bolus 0.1 units/kg and 0.1 units/kg per hour by continuous IV infusion increase two- to threefold if no response by 2–4 h. If the initial serum potassium is <3.3 mmol/L (3.3 meq/L), do not administer insulin until the potassium is corrected.
Slide 32-

DKA management… 6. Assess patient: for the precipitating event and its management 7. Monitering. Measure capillary glucose every 1–2 h electrolytes (especially K+, bicarbonate, phosphate) and anion gap every 4 h for first 24 h. Monitor blood pressure, pulse, respirations, mental status, fluid intake and output every 1–4 h.
Slide 33-

DKA management… 9. Replace K+: when plasma K+ <5.2 meq/L… 10 meq/h (or 20–30 meq/L of infusion fluid) when plasma K+ <3.5 meq/L or if bicarbonate is given. administer 40–80 meq/h serum potassium is >5.2 mmol/L (5.2 meq/L), do not supplement K+ until the potassium is corrected.
Slide 34-

DKA management… 10. bicarbonate or phosphate supplementation. 11. goals include glucose level between8.3–11.1 mmol/L (150–200 mg/dL), and resolution of acidosis 12. Administer long-acting insulin as soon as patient is eating. Allow for a 2–4 hour overlap in insulin infusion and SC long-acting insulin injection.
Slide 35-

HHS Typically.. an elderly individual with type 2 DM, with a several-week history of polyuria, weight loss, and diminished oral intake that culminates in mental confusion, lethargy, or coma. The physical examination reflects profound dehydration and hyperosmolality and reveals hypotension, tachycardia, and altered mental status. Notably absent are symptoms of nausea, vomiting, and abdominal pain and the Kussmaul respirations characteristic of DKA.
Slide 36-

Pathophysiology Lab diagnosis Management Fluid replacement Insulin infusion
Slide 37-

Diabetes in a hospitalized patient (1)A common management guideline for each hospital (2) Diabetes treatment plans should focus on the transition from the ICU (3) Special focus on discharge treatment regimen
Slide 38-

Other considerations in D.M.. TPN GLUCOCORTICOIDS D.M CARE OF OLDER ADULTS REPRODUCTIVE ISSUES LIPODYSROPHIC D.M
Slide 39-

Pictoral quiz
Slide 40-

The gila monster, the saliva of which is the source of exenatide, a GLP1 agonist
Slide 41-

Proinsulin insulin c-peptide
Slide 42-

The Banting and Best with their research dog.
Slide 43-

Rich Piana and Ghent Whakefield. Two of the famous body builders who had probably died of insulin abuse.
Slide 44-

Lipodystrophic DM of forearm, thigh and calf.
Slide 45-

CGM or continuous glucose monitering device(on right) and closed loop insulin based on CGM (on left)
Slide 46-

Thank you